Status:
NOT_YET_RECRUITING
Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders
Lead Sponsor:
University of Sao Paulo General Hospital
Collaborating Sponsors:
Swiss Federal Institute of Technology in Zurich (ETH Zurich)
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Cushing Syndrome
Primary Aldosteronism
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this project is to provide novel technology that will pave the way from the present single-point (analogue) endocrinology towards continuous cortisol and aldosterone monitoring with full t...
Detailed Description
To trace steroid dynamics in a routine setting, the choice of body fluid is critical, as it dictates the ease and frequency of collection that is tolerated by individuals. While the gold standard is b...
Eligibility Criteria
Inclusion
- Individuals (males and females) older than 18 years;
- Patients with primary adrenal insuffiency (cortisol and aldosterone deficiency);
- Patients with Cushing Syndrome (cortisol excess)
- Patients with Primary Aldosteronism (aldosterone excess)
Exclusion
- Use of estrogen-containing oral contraceptive medication within the past 6 weeks;
- Pregnancy or lactation;
- Use of oral, inhaled, parenteral, or topical glucocorticoids within the past 30 days.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT06980753
Start Date
June 1 2025
End Date
December 1 2025
Last Update
May 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of São Paulo - General Hospital
São Paulo, São Paulo, Brazil